Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 17/20 | 0.73 |
| ▸ | GIPR | P48546 | 12/20 | 0.68 |
| ▸ | GCGR | P47871 | 8/20 | 0.68 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399148 | 0.97 | GLP1R (0.76) | GLP1RGIPRGCGR | |
| SCHEMBL29359393 | 0.97 | GLP1R (0.76) | GLP1RGIPRGCGR | |
| SCHEMBL29376189 | 0.97 | GLP1R (0.76) | GLP1RGIPRGCGR | |
| Acetic Acid SCHEMBL29568059 | 0.96 | GLP1R (0.75) | GLP1RGIPRGCGRCXCR4 | |
| Acetic Acid SCHEMBL29533662 | 0.96 | GLP1R (0.75) | GLP1RGIPRGCGRCXCR4 | |
| SCHEMBL31759052 | 0.95 | GLP1R (0.75) | GLP1RGIPRGCGR | |
| SCHEMBL30874225 | 0.95 | GLP1R (0.73) | GLP1RGIPRGCGR | |
| SCHEMBL30473781 | 0.93 | GLP1R (0.73) | GLP1RGIPRGCGR | |
| SCHEMBL30029549 | 0.93 | GLP1R (0.76) | GLP1RGIPRGCGR | |
| SCHEMBL30473787 | 0.93 | GLP1R (0.75) | GLP1RGIPRGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023231433-A1 | LONG-ACTING EXENDIN-9-39 AND USE THEREOF IN HYPOGLYCEMIA TREATMENT AND AS DRUG FOR TREATING HYPOGLYCEMIA | 南京盛德瑞尔医药科技有限公司 | 2023-12-07 | — | — | WO | claimed |
| CN-116606367-A | Long-acting Exendin-9-39 and application thereof in treatment of hypoglycemia and medicament for treating hypoglycemia | 南京盛德瑞尔医药科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| EP-4049673-B1 | GLP-1 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF POST-PRANDIAL HYPOGLYCEMIA OR CONGENITAL HYPERINSULINISM | UNIV PENNSYLVANIA (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250312420-A1 | METHODS AND COMPOSITIONS FOR TREATING HYPOGLYCEMIC DISORDERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025202284-A1 | GLP-1R ANTAGONISTS FOR THE TREATMENT OF CANCER | FIORINA PAOLO (IT) | 2025-10-02 | — | — | WO | disclosed |
| EP-4623928-A1 | GLP-1R ANTAGONISTS FOR THE TREATMENT OF CANCER | Fiorina, Paolo (IT) | 2025-10-01 | — | — | EP | disclosed |
| US-20250195855-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2025-06-19 | — | — | US | disclosed |
| WO-2025085539-A1 | ENGINEERED BACTERIA FOR CELLULAR BARRIER MAINTENANCE AND PROTECTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-118078955-A | ELP fusion proteins for controlled and sustained release | 免疫新炉有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118078956-A | ELP fusion proteins for controlled and sustained release | 免疫新炉有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-2714070-B1 | LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS | OPKO BIOLOGICS LTD (IL) | 2024-03-20 | — | — | EP | disclosed |
| WO-2023231433-A1 | LONG-ACTING EXENDIN-9-39 AND USE THEREOF IN HYPOGLYCEMIA TREATMENT AND AS DRUG FOR TREATING HYPOGLYCEMIA | 南京盛德瑞尔医药科技有限公司 | 2023-12-07 | — | — | WO | disclosed |
| WO-2023231433-A1 | LONG-ACTING EXENDIN-9-39 AND USE THEREOF IN HYPOGLYCEMIA TREATMENT AND AS DRUG FOR TREATING HYPOGLYCEMIA | 南京盛德瑞尔医药科技有限公司 | 2023-12-07 | — | — | WO | disclosed |
| WO-2023231433-A1 | LONG-ACTING EXENDIN-9-39 AND USE THEREOF IN HYPOGLYCEMIA TREATMENT AND AS DRUG FOR TREATING HYPOGLYCEMIA | 南京盛德瑞尔医药科技有限公司 | 2023-12-07 | — | — | WO | disclosed |
| CN-116606367-A | Long-acting Exendin-9-39 and application thereof in treatment of hypoglycemia and medicament for treating hypoglycemia | 南京盛德瑞尔医药科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116606367-A | Long-acting Exendin-9-39 and application thereof in treatment of hypoglycemia and medicament for treating hypoglycemia | 南京盛德瑞尔医药科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116606367-A | Long-acting Exendin-9-39 and application thereof in treatment of hypoglycemia and medicament for treating hypoglycemia | 南京盛德瑞尔医药科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-109310736-B | Hafnia alvei-based pharmaceutical and food compositions for inducing satiety and prolonging satiety | 国立卫生研究所 | 2022-09-13 | — | — | CN | disclosed |
| EP-4049673-A1 | GLP-1 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF POST-PRANDIAL HYPOGLYCEMIA OR CONGENITAL HYPERINSULINISM | The Trustees of the University of Pennsylvania (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-3456340-B1 | GLP-1 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF CONGENITAL HYPERINSULINISM | UNIV PENNSYLVANIA (US) | 2022-02-16 | — | — | EP | disclosed |